Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study

  • Verona Pharma PLC VRNA has reported positive data from the Phase 2 study evaluating pressurized metered-dose inhaler formulation (pMDI) of ensifentrine in moderate to severe chronic obstructive pulmonary disease. The study met all primary and secondary endpoints. 
  • Dose-ordered improvement in lung function was observed and statistically significant at peak and over the 12-hour dosing interval compared with placebo, thus supporting twice-daily dosing.
  • An increase in lung function measured by peak forced expiratory volume in one second (FEV1) were 205 mL, 277mL, and 326mL for 300 µg, 1000 µg, and 3000 µg dose, respectively.
  • Ensifentrine pMDI formulation was well tolerated at each dose with an adverse event profile similar to placebo.
  • The drug candidate is also under development in hospitalized COVID-19 patients, with results expected in Q2 this year.
  • Price Action: VRNA shares are higher by 13.4% at $8.96 in the pre-market session on the last check Tuesday.

Posted In: chronic obstructive pulmonaryPhase 2 Clinical TrialBiotechNewsSmall CapFDATop StoriesGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.